Abgenix Inc.'s belt-tightening move that consolidates its research and preclinical activities into its Canadian facility in Burnaby, British Columbia, and lays off about 15 percent of its work force will give the firm more resources to direct toward panitumumab, the fully human monoclonal antibody for colorectal cancer partnered with Amgen Inc. (BioWorld Today) Read More
